These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The facility will manufacture tablets, capsules, and injections for the oncology segment
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Operations of Line II was stopped due to a fire incident earlier
Hepatitis B infects over 40 million people in India
Subscribe To Our Newsletter & Stay Updated